Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2008, Vol. 13 ›› Issue (1): 6-10.
Previous Articles Next Articles
ZHANG Ke-han, LIU Zhao-qian
Received:
2007-10-11
Revised:
2007-12-27
Online:
2008-01-26
Published:
2020-10-13
CLC Number:
ZHANG Ke-han, LIU Zhao-qian. Physiological action of peroxisome proliferator activated receptor γcoactivator-1 and its relationship with type 2 diabetes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(1): 6-10.
[1] Puigserver P, Wu Z, Park CW, et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis[J]. Cell, 1998, 92(6): 829-839. [2] Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1[J]. Cell, 1999, 98(1): 115-124. [3] Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction[J]. Nature, 2003, 423(6939): 550-555. [4] McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators[J]. Cell, 2002, 108(4): 465-474. [5] Soyal S, Krempler F, Oberkofler H, et al. PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes[J]. Diabetologia, 2006, 49(7): 1477-1488. [6] Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease[J]. J Clin Invest, 2006, 116(3): 615-622. [7] Esterbauer H, Oberkofler H, Krempler F, et al. Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression[J]. Genomics, 1999, 62(1): 98-102. [8] Pratley RE, Thompson DB, Prochazka M, et al. An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians[J]. J Clin Invest, 1998, 101(8): 1757-1764. [9] Heery DM, Kalkhoven E, Hoare S, et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors[J]. Nature, 1997, 387(6634): 733-736. [10] Ichida M, Nemoto S, Finkel T. Identification of a specific molecular repressor of the peroxisome proliferator-activated receptor gamma Coactivator-1 alpha (PGC-1alpha)[J]. J Biol Chem, 2002, 277(52): 50991-50995. [11] Rhee J, Inoue Y, Yoon JC, et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis[J]. Proc Natl Acad Sci USA, 2003, 100(7): 4012-4017. [12] Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator[J]. Endocr Rev, 2003, 24(1): 78-90. [13] Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function[J]. Genes Dev, 2004, 18(4): 357-368. [14] Baar K, Wende AR, Jones TE, et al. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1[J]. FASEB J, 2002, 16(14): 1879-1886. [15] Wu H, Kanatous SB, Thurmond FA, et al. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK[J]. Science, 2002, 296(5566): 349-352. [16] Schaeffer PJ, Wende AR, Magee CJ, et al. Calcineurin and calcium calmodulin-dependent protein kinase activate distinct metabolic gene regulatory programs in cardiacmuscle[J]. J Biol Chem, 2004, 279(38): 39593-39603. [17] Handschin C, Rhee J, Lin J, et al. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle[J]. Proc Natl Acad Sci USA, 2003, 100(12): 7111-7116. [18] Michael LF, Wu Z, Cheatham RB, et al. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1[J]. Proc Natl Acad Sci USA, 2001, 98(7): 3820-3825. [19] Wende AR, Huss JM, Schaeffer PJ, et al. PGC-1alpha coactivates PDK4 gene expression via the orphan nuclear receptor ERRalpha: a mechanism for transcriptional control of muscle glucose metabolism[J]. Mol Cell Biol, 2005, 25(24): 10684-10694. [20] Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres[J]. Nature, 2002, 418(6899): 797-801. [21] Oberkofler H, Schraml E, Krempler F, et al. Potentiation of liver X receptor transcriptional activity by peroxisomeproliferator-activated receptor gamma co-activator 1 alpha[J]. Biochem J, 2003, 371(Pt 1): 89-96. [22] Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivatorPGC-1[J]. Nature, 2001, 413(6852): 131-138. [23] Lin J, Yang R, Tarr PT, et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP[J]. Cell, 2005, 120(2): 261-273. [24] PattiME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1[J]. Proc Natl Acad Sci USA, 2003, 100(14): 8466-8471. [25] Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes[J]. Nat Genet, 2003, 34(3): 267-273. [26] Ling C, Poulsen P, Carlsson E, et al. Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins[J]. J Clin Invest, 2004, 114(10): 1518-1526. [27] Wilson-Fritch L, Nicoloro S, Chouinard M, et al. Mitochondrial remodeling in adipose tissue associated with obe-sity and treatment with rosiglitazone[J]. J Clin Invest, 2004, 114(9): 1281-1289. [28] Yoon JC, Xu G, Deeney JT, et al. Suppression of beta cell energy metabolism and insulin release by PGC-1alpha[J]. Dev Cell, 2003, 5(1): 73-83. [29] Koo SH, Satoh H, Herzig S, et al. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3[J]. Nat Med, 2004, 10(5): 530-534. [30] Ek J, Andersen G, Urhammer SA, et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus[J]. Diabetologia, 2001, 44(12): 2220-2226. [31] Andersen G, Hansen T, Gharani N, et al. A common Gly482Ser polymorphism of PGC21 is associated with type 2 diabetes mellitus in two European population[J]. Diabetes, 2002, 51(Suppl 2): A49. [32] Lacquemant C, ChikriM, Boutin P, et al. No association between the G482S polymorphism of the proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene and Type II diabetes in French Caucasians[J]. Diabetologia,2002, 45(4): 602-603. [33] Vimaleswaran KS, Radha V, Ghosh S, et al. Peroxisome proliferator-activated receptor-gamma co-activator-1alpha (PGC-1alpha) gene polymorphisms and their relationship to Type 2 diabetes in Asian Indians[J]. Diabet Med, 2005, 22(11): 1516-1521. [34] Hara K, Tobe K, Okada T, et al. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes[J]. Diabetologia, 2002, 45(5): 740-743. [35] 王艳波, 于永春, 李智, 等. 中国上海地区汉族人PGC-1α基因多态性与2 型糖尿病相关性研究[J]. 中华医学遗传学杂志, 2005, 22(4): 453-456. |
[1] | LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282. |
[2] | LIU Yizhen, REN Lingxuan, YANG Jianjun, HE Jianyu, LIU Xiaojun, WANG Long, LIN Rong. Study on the screening of active constituents of Taohong Siwu Decoction and the protective effect of ferulic acid on myocardial injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 505-515. |
[3] | JIN Jing, CHENG Hong. Research progress of mitochondrial energy metabolism involved in the pathogenesis of depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1193-1199. |
[4] | LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006. |
[5] | LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059. |
[6] | HAN Chenyang, ZHANG Xiaoling, GUAN Qiaobin, WANG Yanping. Effects of NBP on energy metabolism of human brain microvascular endothelial cells under the condition of glucose deprivation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1329-1334. |
[7] | CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa. Relevance of CYP1B1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316. |
[8] | ZHOU Yuan, LU Xueling, ZHAO Jun, ZHANG Li, YANG Huanjie,WANG Ning. Polymorphism distribution of rs316019 of SLC22A2 in the Uygur population of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 287-293. |
[9] | LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao. Genetic research on the incidence of alcoholic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314. |
[10] | HU Jing, ZHU Jun-rong, YU Feng. Efficacy and safety of warfarin dosage algorithms in clinical application:A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 296-303. |
[11] | MA Xiao-qin, XIN Hua-wen, LI Yuan-qi, HUANG Hui, ZHAO Li, YU Ai-rong, LI Wei-liang, WU Xiao-chun. Association of HGPRT activity and gene polymorphism with adverse reactions caused by azathioprine in kidney transplant recipients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 182-187. |
[12] | WU Ji-chu, OUYANG Ze-wei, LUO Can-xiang. Effect of ABCG2 genetic polymorphism on atorvastatin modifying serum lipids [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 882-884. |
[13] | OUYANG Cang-hong, XIE Juan. Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 291-296. |
[14] | FENG Jing, WU Yue, RONG Pei-pei, SHEN Bing-zheng, ZHOU Ding-shan, SHI Cai, SONG Jin-chun. Progress on effects of pharmacogenetics of inosine triphosphate pyrophosphatase on improving the individualized thiopurine therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1435-1440. |
[15] | HUANG Lu, YANG Guo-ping. Progress on influence of cytochrome P450 oxidoreductase polymorphisms on cytochrome P450 monoxyfenases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 818-823. |
Viewed | ||||||||||||||||||||||||||||||||||
Full text |
|
|||||||||||||||||||||||||||||||||
Abstract |
|
|||||||||||||||||||||||||||||||||